Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06868927

Acronym

TARGET-RCC

Enrollment

Registered

2025-03-11

Start date

2025-09-26

Completion date

2029-12-31

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Tumors

Brief summary

This project aims to provide an accurate strategy to guide the decision making relying on tumor biopsies using standard histology, immunohistochemistry (IHC), spatial transcriptomics, genomics combined with Magnetic Resonance Imaging (MRI) and radiomics. Moreover, the investigators will explore potential markers indicative of response to systemic agents or ablative therapy.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presence of a renal mass up to 4 cm * Adult \> 18 years * Candidate to renal surgery * Informed consent signed

Exclusion criteria

* Contraindication for MRI

Design outcomes

Primary

Measure	Time frame	Description
accuracy of multiparametric preoperative MRI	At final pathological assessment , at least 1 month after surgery	Detection of "Unfavourable outcome" is defined as the presence of at least one of the following pathological characteristics: * High grade tumor (G3 or G4) * Not-organ confined disease (pT3 and or pT4 and/or LNI) * Sarcomatoid features

Countries

Italy

Contacts

CONTACTUmberto Capitanio

caitanio.umberto@hsr.it3492503788

Outcome results